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Background: Cumulative anticholinergic exposure, also known as anticholinergic burden,
is associated with a variety of adverse outcomes. However, studies show that
anticholinergic effects tend to be underestimated by prescribers, and anticholinergics
are the most frequently prescribed potentially inappropriate medication in older patients.
The grading systems and drugs included in existing scales to quantify anticholinergic
burden differ considerably and do not adequately account for patients’ susceptibility to
medications. Furthermore, their ability to link anticholinergic burden with adverse
outcomes such as falls is unclear. This study aims to develop a prognostic model that
predicts falls in older general practice patients, to assess the performance of several
anticholinergic burden scales, and to quantify the added predictive value of anticholinergic
symptoms in this context.
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Methods: Data from two cluster-randomized controlled trials investigating medication
optimization in older general practice patients in Germany will be used. One trial (RIME, n 
1,197) will be used for the model development and the other trial (PRIMUM, n  502) will be
used to externally validate the model. A priori, candidate predictors will be selected based
on a literature search, predictor availability, and clinical reasoning. Candidate predictors will
include socio-demographics (e.g. age, sex), morbidity (e.g. single conditions), medication
(e.g. polypharmacy, anticholinergic burden as defined by scales), and well-being (e.g.
quality of life, physical function). A prognostic model including sociodemographic and
lifestyle-related factors, as well as variables on morbidity, medication, health status, and
well-being, will be developed, whereby the prognostic value of extending the model to
include additional patient-reported symptoms will be also assessed. Logistic regression
will be used for the binary outcome, which will be defined as “no falls” vs. “≥1 fall”within six
months of baseline, as reported in patient interviews.
Discussion: As the ability of different anticholinergic burden scales to predict falls in older
patients is unclear, this study may provide insights into their relative importance as well as
into the overall contribution of anticholinergic symptoms and other patient characteristics.
The results may support general practitioners in their clinical decision-making and in
prescribing fewer medications with anticholinergic properties.
Keywords: aged [MesH], anticholinergic burden, accidental falls [MeSH], general practice, prediction model,
prognosis research, multimorbidity [MeSH], polypharmacy
INTRODUCTION
Medications with anticholinergic (ACh) properties are
commonly used for a variety of indications (Jessen et al., 2010;
Wawruch et al., 2012; Mate et al., 2015) and, along with sedatives,
are the most frequently prescribed potentially inappropriate
medications (PIM) in older adults (Hukins et al., 2019).
Depending on patient population and setting, the prevalence
of ACh drug use varies between 27% in community-based elderly
patients (Ness et al., 2006) and up to 80% in more vulnerable
populations such as older patients receiving home health care
services or nursing home patients with dementia (Chatterjee
et al., 2010; McNeely et al., 2013).
The terms “anticholinergic symptoms,” “anticholinergic side-
effects,” “anticholinergic adverse effects” and “adverse drug
reactions” have been used interchangeably to describe
peripheral and central effects associated with anticholinergic
drug use, including, for example dry mouth, dry skin, blurred
vision, and drowsiness (Ness et al., 2006; Mintzer and Burns,
2016; Welsh et al., 2018). Moreover, anticholinergics have been
associated with a variety of adverse outcomes, the most important
of which include falls and quality of life, as well as cognitive and
functional decline (Cardwell et al., 2015; Welsh et al., 2018).
Falling, in particular, is a significant public health issue and
represents the leading cause of disability and death in older
age. It is further associated with an increase in mortality,
morbidity, hospital admissions and costs for treatments
(National Institute for Health and Care Excellence, 2013;
Verma et al., 2016). The prevention of falls is therefore highly
relevant and should be addressed by healthcare professionals
involved in the care of older patients (National Institute for
Health and Care Excellence, 2013). Gait and balance disorders,
muscle weakness, and cognitive impairment all increase the risk
of falling with advanced age (Deandrea et al., 2010). The high
volume of ACh drug prescriptions raises concerns in terms of
appropriateness and patient safety. This is especially true in older
age, as it is associated with an increased likelihood of multiple
chronic conditions (multimorbidity) and subsequent long-term
medication use (polypharmacy), which may further lead to an
accumulation of effects and result in substantial harm (Thomas
and Brennan 2000; Hilmer et al., 2007a; Delafuente, 2008; Gnjidic
et al., 2012; Kouladjian O’Donnell et al., 2017).
Salahudeen et al. have shown that older patients taking
multiple ACh agents are 3.21 times more likely to experience
ACh symptoms than those taking only one (Salahudeen et al.,
2015b), underlining the potential risk of accumulating ACh
effects, also known as ACh burden. However, ACh burden
tends to be underestimated by general practitioners (GPs)
(Magin et al., 2015). As a recent review of systematic reviews
identified at least 18 different scales that have been developed and
are used in a variety of clinical settings (Welsh et al., 2018), such
underestimation may reflect the lack of an universal approach to
quantifying ACh burden. These scales not only differ
considerably in the way they are conducted and the (number
of) included drugs, but also in their grading systems (Salahudeen
et al., 2015a; Villalba-Moreno et al., 2016; Mayer et al., 2017;
Welsh et al., 2018). For example, quetiapine is rated as having
high or low activity, depending on the scale (Salahudeen et al.,
2015a). Furthermore, the scales were developed based on expert
opinions (Villalba-Moreno et al., 2016; Welsh et al., 2018) and
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with two exceptions (Hilmer et al., 2007b; Klamer et al., 2017), do
not consider drug dose, or adequately account for patients’
individual characteristics such as sex, age, morbidity, and
individual susceptibility to medications (Cardwell et al., 2015;
Mayer et al., 2015).
The ability of scales to link ACh burden with numerous
adverse outcomes has been inconsistently described in a
variety of studies (Cardwell et al., 2015; Salahudeen et al.,
2015a; Villalba-Moreno et al., 2016; Mayer et al., 2017; Welsh
et al., 2018). A recent review of systematic reviews identified 62
original articles that focused mainly on the outcomes cognitive
function, physical function, mortality, and delirium (Welsh et al.,
2018). Little research has been undertaken to determine the
predictive ability of ACh scales in relation to falls. The few
studies that exist on this issue have generally involved
vulnerable patient populations [e.g., from nursing homes and
hospitals (Aizenberg et al., 2002; Landi et al., 2014; Vincentis
et al., 2020)]. Findings from community-based settings or from
general practice are not only scarce but also show inconsistent
results (Marcum et al., 2015; Richardson et al., 2015; Zia et al.,
2016). Furthermore, these trials, as well as ACh scales in general,
were mainly conducted outside Germany (Carnahan et al., 2006;
Hilmer et al., 2007b; Wilson et al., 2011; Dauphinot et al., 2014;
Villalba-Moreno et al., 2016). It therefore remains unclear
whether such scales are useful in clinical practice and whether
they support clinical decision-making in the prescription of
medications with ACh properties, for example in a German
healthcare context.
The aims of this study are:
1. To develop and validate a prognostic model that considers
patients’ individual characteristics in predicting the risk of falls
in older general practice patients.
2. To assess the performance of several ACh burden scales in this
context and to identify the one that best predict falls, and
3. To quantify whether the addition of patient-reported ACh
symptoms improves the model’s predictive performance.
METHODS
Source of Data
Data from the international PROPERmed study (PROSPERO ID:
CRD42018088129) will be used to develop the model.
PROPERmed includes individual participant data from five
cluster-randomized controlled trials (cRCTs) conducted in
German and Dutch general practices that were combined to
form a harmonized database for modelling purposes. cRCTs
included in PROPERmed aimed to optimize medication in
older chronically ill patients from general practices. Based on
the core dataset that included variables on socio-demographics,
well-being, morbidity, and medication, two prognostic models
were developed that predict deterioration of health-related
quality of life (González-González et al., 2020) and all-cause
hospitalization (Meid et al., submitted). Details on the
rationale and conduct of PROPERmed will be described
elsewhere (González-González et al., re-submitted). To address
the research question in our study, other variables in addition
to PROPERmed’s core dataset are needed from the trials, which
include variables on falls as well as on ACh symptoms (e.g.,
vertigo/dizziness, dry mouth). To avoid systematically missing
variables, only trials that are able to provide the set of additional
variables will be considered for our study. Therefore, we will only
consider data from the two trials RIME (Thiem et al., 2020) and
PRIMUM (Muth et al., 2018) for model development. Both
cRCTs were conducted in German general practices and
aimed to optimize medication in older chronically ill patients
from this setting. The main characteristics of PRIMUM and
RIME are provided in Table 1.
Participants
Participants in both trials were older patients from German
general practices. In PRIMUM, 502 participants aged
≥60 years with ≥3 chronic conditions and ≥5 chronic
prescriptions were included. RIME included 1,197 patients
aged ≥70 years with ≥6 chronic prescriptions. To take part in
the trials, participants had to provide written informed consent
and be capable of participating in telephone interviews and
understanding the provided information. Patients with
dementia or cognitive impairment and patients with a life
expectancy of less than six months (RIME) or 12 months
(PRIMUM) were excluded from participation.
Outcome
Based on the data provided in patient interviews, the study
outcome of interest will be a binary indicator defined as “no
falls” vs. “≥1 fall” within six months of baseline as reported in
patient interviews. Patient interviews were conducted on the
telephone by trained staff, whereby information concerning
falls was gathered by asking the following question: “In the
past six months, have you slipped, stumbled, or fallen, such
that you lost your balance and landed in a lower position or
on the ground?”
Predictors
Research has identified numerous predictors for falls in the
elderly such as socio-demographics (e.g. age, sex),
physiological, and morbidity-related factors (e.g., gait and
balance problems, dementia, depression), environmental
factors (e.g., home, footwear), and medication-related factors
(Deandrea et al., 2010; Ambrose et al., 2013; Zia et al., 2015;
Sousa et al., 2017). Rather than include such a wide range of
variables, we will follow recommendations on variable selection
in prediction models that they should be clearly defined, available
in medical practice, and measured in a reproducible and
standardized way to improve the applicability and predictive
ability of the model in new individuals (Moons et al., 2012b;
Hendriksen et al., 2013; Harrell 2019). If the number of outcomes
in the dataset is limited, the authors further recommend
restricting the number of predictors in order to avoid
overfitting the model to the data and erroneously including
predictors in the model (Hendriksen et al., 2013; Moons et al.,
2012b). The candidate predictors considered for our model will
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therefore be predefined based on a) a literature review, b)
predictor availability in the included trials (RIME and
PRIMUM), and c) clinical reasoning. The full list of
candidate predictors and how they were measured is
provided in Table 2. All predictor information was collected
at baseline and includes sociodemographic and lifestyle-related
factors, variables on morbidity, health status, well-being,
symptoms and medication. The analyses will only consider
medication with systemic effect. In accordance with Brueckle
et al. (Brueckle et al., 2020), the following symptoms available in
the RIME trial are considered to be anticholinergic drug
reactions and will be included as potential predictors in our
analyses: dizziness/vertigo, stomach pain, problems urinating,
dry mouth, itching, constipation, drowsiness/fatigue. ACh
burden, in particular, will be measured using five differenct
scales/equations with the aim of comparing their ability to
predict falls. An overview of ACh scales’ characteristics is
presented in Table 3. For our study, we have selected the
scales that were found to be frequently used in the review of
systematic reviews examining the association between ACh
burden and patient-relevant outcomes published by Welsh
et al. (2018): the Anticholinergic Drug Scale (ADS)
(Carnahan et al., 2006), the Anticholinergic Risk Scale (ARS)
(Rudolph et al., 2008) and the Drug-Burden-Index (DBI)
(Hilmer et al., 2007b). We will further include the
Muscarinic Acetylcholinergic Receptor ANTagonist Exposure
Scale (MARANTE) (Klamer et al., 2017), as this scale combines
potency with the dosage spectrum as well as the German
Anticholinergic Burden Score (Ger-ABS) (Kiesel et al., 2018),
as it is the only scale that was explicitly developed for the
German drug market. In the two studies RIME and PRIMUM,
prescribed drugs were coded based on the Anatomic
Therapeutic Chemical (ATC) classification. For our analyses,
ACh burden will be calculated in accordance with the scales’
definitions, and respective ATC codes for the German drug
market will be identified accordingly. For the calculation of the
DBI, the minimum recommended daily dose as listed by the US
Food and Drug Administration (FDA) is required (Kouladjian
et al., 2014) As minimum recommended daily doses vary
between countries, we will use a version of the DBI that was
adapted for the German drug market in the COFRAIL-study by
Thürmann et al. (German Innovation Funds No. 01VSF17053).
Candidate predictors collected as continuous measurements
will be kept continuous in the analyses. We will assume
continuous candidate predictors to be linearly associated with
the outcome with the exception of ACh variables, for which
research has shown that high ACh load appears to reach a
plateau, indicating a non-linear relationship (Kersten et al.,
2013; Mayer et al., 2015).
Sample Size
When designing a prediction model study, Riley et al. (2019)
recommend that the minimum sample size is calculated to meet
certain criteria and minimize overfitting. As we will
retrospectively analyze individual participant data, the
sample size and prevalence are already given by the included
trials. The pmsampsize package in R provided by the authors
will be used to calculate whether our sample size meets the
suggested criteria, and, in view of the number of predictors, to
determine the level of expected overfitting of our model (Ensor
et al., 2019). We will use data from the RIME study for model
development because of its larger sample size (n  1,197 vs. n 
502) and larger number of events (n  202 vs. n  75) compared
to PRIMUM.
Missing Data
If a predictor is not present in either of the included studies, it will
be considered systematically missing for that study. For practical
reasons, systematically missing variables will not be imputed and
will therefore not be considered candidate predictors in model
development.
Because the exclusion of participants with missing values from
analyses (as in complete case analyses) reduces the effective
sample size and may lead to biased estimates, we will follow
recommendations on dealing with the missing values that
inevitably occur in predictors and use multiple imputation
(MI) techniques to impute partially missing data (Moons
et al., 2012b; Harrell 2015). In the first stage of MI, multiple
datasets will be created and the missing values imputed based on
the observed data and on the assumption that data are missing at
TABLE 1 | Main characteristics of the included trials.
PRIMUM RIME
Title PRIoritizing MUltimedication in Multimorbidity Reduction of potentially inadequate medication in the Elderly
Trial registration ISRCTN99526053, NCT01171339 DRKS00003610
Study region Hesse (Germany) Witten/Hanover (Germany)
Start-end 2010–2012 2012–2014
Design 2-arm parallel CRT 2-arm parallel CRT
Setting General practices (N  72) General practices (N  139)
Study population N  502 N  1,197
≥60 years ≥70 years
≥3 chronic conditions ≥6 chronic prescriptions
≥5 chronic prescriptions
Intervention Structured medication review Structured medication review
Data collection 0, 6, and 9 months 0, 6, and 12 months
No. of patients with ≥1 fall at 6-month follow-up 75 202
CRT, cluster-randomized trial.
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random. The imputation will then be repeated multiple times to
properly account for variability in the imputation process. As an
approximation, the number of imputed datasets (m) will
correspond to the percentage of incomplete observations
(White et al., 2011). The analyses will be performed for each
dataset, resulting in m analysis results. The last step of MI is a
pooling step, whereby overall estimates will be obtained using
Rubin’s rules (White et al., 2011; Harrell 2015). In line with the
reporting suggestions of Sterne et al., we will compare results
from complete cases compared with results based on MI in order
to be able to detect and understand differences between them
(Sterne et al., 2009).
Statistical Analysis Methods
All statistical analyses will be conducted using R version 4.0 (R
Foundation for Statistical Computing, Vienna, Austria).
TABLE 2 | Candidate predictors available in the development dataset.
Group Type of
predictor





Intervention status Registration form Cat Intervention, control
Age Registration form Cont Years
Sex Registration form Cat Male, female
Living situation Patient interview Cat Home, institutionalized
Educational CRF Cat Low, medium, high
Smoking Patient interview Cat Smoker, ex-smoker,
non-smoker
B Morbidity-related Hypertension Patient interview Bin No, yes
Diabetes mellitus Patient interview Bin No, yes
Coronary heart disease Patient interview Bin No, yes
Osteoarthritis Patient interview Bin No, yes
COPD/asthma Patient interview Bin No, yes
Vision problems Patient interview Bin No, yes
Hearing problems Patient interview Bin No, yes
Cancer Patient interview Bin No, yes
Heart failure Patient interview Bin No, yes
Cerebrovascular disease Patient interview Bin No, yes
Osteoporosis Patient interview Bin No, yes
Depression Patient interview Bin No, yes
Rheumatoid/seropositive arthritis Patient interview Bin No, yes
Atherosclerosis/peripheral vascular disease Patient interview Bin No, yes
Parkinsonism Patient interview Bin No, yes
HIV/AIDS Patient interview Bin No, yes
Lipid disorder Patient interview Bin No, yes
Gout Patient interview Bin No, yes
Thyroid disorders Patient interview Bin No, yes
Gastric or duodenal ulcer Patient interview Bin No, yes
Liver disorder Patient interview Bin No, yes
Urinary disease Patient interview Bin No, yes
Anemia Patient interview Bin No, yes
No. of chronic conditions Patient interview Cont No, yes
C Health status and well-being
related
Pain Patient interview Bin No, yes
Quality of life (EuroQol Group 1990) Patient interview Cont Score
Functional status (Saliba et al., 2001) Patient interview Cont Score
Cognitive function Patient interview Cont Score
All-cause hospital admissions Patient interview Bin No, yes
History of falls Patient interview Cat ≤1 fall, ≥ 2 falls
D Medication related No. of drugs Patient interview Cont Frequency
ACh burden (Carnahan et al., 2006; Hilmer et al., 2007b;
Rudolph et al., 2008; Klamer et al., 2017; Kiesel et al., 2018)
Calculated using medication
data from patient interview
Cont Weighted index
E Symptoms No. of symptoms Patient interview Cont Frequency
Dizziness/vertigo Patient interview Bin No, yes
Problems urinating Patient interview Bin No, yes
Stomach pain Patient interview Bin No, yes
Patient interview Bin No, yes
Drowsiness/fatiguea Patient interview Bin No, yes
Dry moutha Patient interview Bin No, yes
Itchinga Patient interview Bin No, yes
Constipationa Patient interview Bin No, yes
ACh, anticholinergic; Bin., binary; Cat., categorial; Cont., continuous; COPD, chronic obstructive pulmonary disease; CRF, case report form; HIV/AIDS, human immunodeficiency virus/
acquired immune deficiency syndrome; No, number.
aSymptoms only available in the development dataset (RIME).
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Model Development, Performance and Internal
Validation
The model will be built as follows (see Figure 1).
Model 1. Base Model
First, multivariable logistic regression will be used to develop a base
model that employs data from the RIME trial to predict falls within
six months of baseline. To find the best combination of candidate
predictors (groups A to C), the multivariable fractional polynomial
(MFP) approach will be used. The MFP approach is a procedure
that builds the model, while simultaneously determining a suitable
functional form for continuous variables. It starts with a full model
that includes all candidate predictors and removes the least
significant variables via backward elimination. The choice of
predictors for elimination will be based on Akaike’s Information
Criterion (AIC) (Sauerbrei et al., 2020).
TABLE 3 | Overview of anticholinergic scales’ characteristics.
Study (year) Scale Country No of included drugs Grading system Dosage considered
Carnahan et al. (2006) Anticholinergic drug scale (ADS) USA 117 Scores: 0–3 No
Klamer et al. (2017) Muscarinic acetylcholinergic receptor ANTagonist
exposure scale (MARANTE)
Belgium 41 Equation Yes
Hilmer et al. (2007b) Drug-burden-index (DBI) Australia 128 Equation Yes
Rudolph et al. (2008) Anticholinergic risk scale (ARS) USA 49 Scores: 0–3 No
Kiesel et al. (2018) German anticholinergic burden score (Ger-ABS) Germany 151 Scores: 0–3 No
FIGURE 1 | Model development and validation process.
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Model 2. Base Model + Scale
Secondly, we will add variables on ACh burden (group D) to
the base model. Here, we aim to compare different models for
each of the four scales and one equation that measure ACh
burden (Carnahan et al., 2006; Hilmer et al., 2007b; Rudolph
et al., 2008; Klamer et al., 2017; Kiesel et al., 2018). We will
assess the apparent performance of the models for
discrimination using the c-statistic [equal to the area under
the receiver operating characteristic curve (ROC)] and the
model fit using AIC. The preferred model will be the one with
the lowest AIC and the highest c-statistic. A c-statistic close to
one indicates excellent discrimination and 0.5 indicates that
the model cannot discriminate between individuals that have
the outcome and those that do not (Steyerberg and Vergouwe
2014).
Model 3. Base Model + Chosen Scale + Symptoms
In a third step, we will extend the model by adding symptom
variables (group E) and quantify whether adding these variables
to the developed model is beneficial. The development and
validation datasets have three symptoms in common:
dizziness/vertigo, problems urinating, and stomach pain. The
development dataset includes four further symptoms:
drowsiness/fatigue, dry mouth, itching, and constipation (see
Table 2). We will therefore develop two different models at
this stage: model 3A (Base model + chosen scale + common
symptoms), which will be considered for external validation, and
model 3B (Base model + chosen scale + all symptoms), which will
be developed to conduct an exploratory assessment of whether
the additional variables considerably improve predictive
performance.
Prior to comparing performance, models 2, 3A, and 3B will
be internally validated using bootstrapping. This approach
includes: 1) generating a bootstrap sample, 2) developing the
model using that bootstrap sample, 3) determining the
predictive performance of the model in the bootstrap and
the original samples, 4) calculating optimism as the
difference in performance between bootstrap and the
original samples for each performance measure, 5) repeating
steps 2 to 4, 100 times, and 6) averaging the estimates of
optimism and subtracting average optimism from the
apparent performance of the original model in the original
dataset to obtain optimism-adjusted performance estimates
(Moons et al., 2015). If necessary, we will shrink coefficients
to correct for overfitting.
After internal validation, we will compare the performance
and discriminative ability of the models before and after
adding the variables on anticholinergic symptoms (model 2
vs. model 3A). In case of high collinearity between the
predictors, we will assume that adding symptoms will not
improve model performance (Harrell 2015). We will compare
the c-statistics of the models and determine the change in AIC
(Moons et al., 2012a; Cook 2018). The model with the higher
c-statistic and lower AIC will be selected for external
validation. Because the validation dataset does not include
all symptoms contained in model 3B (base model + chosen scale
+ all symptoms), this model will not be considered for external
validation. However, the use of internal validation to compare
the performance of models 3A and 3B may indicate whether
the additional symptoms considerably improve predictive
performance.
External Validation
Using the PRIMUM dataset, we will externally validate the final
model and assess discriminative ability by estimating the
observed/expected ratio (comparing the predicted number of
falls from our final model with the observed number of falls
in PRIMUM) and the c-statistic. We will further calculate the
calibration slope, calibration-in-the-large, and produce a
calibration plot (Steyerberg et al., 2010).
ANTICIPATED RESULTS
Our results are expected to contribute to the ongoing discussion
regarding the use of ACh scales in clinical practice. Analyses may
identify differences in the scales’ ability of linking ACh burden
with falls for older general practice patients, indicating their
usefulness in clinical practice in a German health care context.
Patients’ individual characteristics and patient-reported
symptoms may reflect clinically relevant and feasible indicators
to identify patients from a heterogeneous population that might
be at high risk of experiencing falls.
Strengths
As one of the limitations of ACh scales’ is their failure to take into
account individual patient characteristics, patient-reported
symptoms may function as a surrogate for patient
susceptibility to such medications and may therefore help
clinicians identify patients at high risk of falls. Furthermore, a
prognostic model tends to perform optimistically when using the
data from which it was derived. It is therefore necessary to assess
its accuracy by externally validating it using a separate dataset
(Moons et al., 2015). External validation will enable to
demonstrate its predictive value and generalizability in a
similar population but with different individuals (Steyerberg
and Vergouwe, 2014).
Limitations
One limitation is the risk of recall-bias in the patients’ ability to self-
report falls (Gillespie et al., 2012). A verification of patient-reported
falls in electronic medical records (EMR) was not possible in the
studies because are not systematically documented in EMRs. The
eligibility criteria and availability of data will not allow us to include
some of the known risk factors for falls in the elderly such as
dementia, muscle strength, or gait problems (Deandrea et al., 2010;
Ambrose et al., 2013; Sousa et al., 2017). It will also prevents us
from considering the known increased risk of inter-individual
variability in older age that results from, for example, age-
related pharmacokinetic and pharmacodynamic changes and
genetic variation in metabolism (Nishtala et al., 2016).
Furthermore, we are not able to prove the causality of the
symptoms, as they may have been caused by factors other than
a (anticholinergic drug) reaction to the medication. Nevertheless,
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as patients’ susceptibility varies considerably, we believe that taking
patient-reported symptoms into consideration will provide
additional decision support to the mere calculation of
anticholinergic load (Kersten and Wyller, 2014). As external
validation will be carried out retrospectively using an existing
dataset, the 75 events from PRIMUM will not meet the
suggested minimum of 100 events required to externally
validate a prognostic model (Collins et al., 2016). In
consequence, we expect estimates of performance measures to
have relatively wide 95% confidence intervals. In view of this
limitation, we will carefully discuss and interpret our findings.
DISCUSSION
Literature on ACh scales’ ability to predict falls is scarce. This
study may therefore provide insights into the issue by comparing
the measurements provided by several scales with the number of
falls and determining whether the inclusion of patient-reported
symptoms is beneficial in this context. Our results may therefore
support GPs with their clinical decision-making in reducing
medications with ACh properties in older patients.
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